Grace Xu

Ms. Xu’s representations (including those from her prior firm) include:

Capital Markets

• Lufax Holding Ltd in the dual-primary listing of its ordinary shares by way of introduction on the Hong Kong Stock Exchange
• Keymed Biosciences Inc. in its US$458 million initial public offering and listing on the Hong Kong Stock Exchange
• RemeGen Co., Ltd. in its US$515 million initial public offering and listing on the Hong Kong Stock Exchange, which was the world’s largest primary listing and IPO in 2020 for a biopharmaceutical issuer in terms of proceeds raised
• Akeso Biopharma in its US$383 million initial public offering and listing on the Hong Kong Stock Exchange
• Zero2IPO Holdings Inc. in its US$56.8 million primary listing on the Hong Kong Stock Exchange (representing the underwriters)
• Yeahka Limited in its US$212 million initial public offering and listing on the Hong Kong Stock Exchange
• FingerTango Inc. in its US$133 million initial public offering and listing on the Hong Kong Stock Exchange (representing the underwriters)
• Digital Hollywood Interactive Limited in its US$40 million initial public offering and listing on the Hong Kong Stock Exchange (representing the underwriters)
• Alibaba Group Holding Limited in its:
  • US$25 billion initial public offering and listing on the New York Stock Exchange
  • US$8 billion senior unsecured notes offering
• Jingrui Holdings Limited in its:
  • US$220 million initial public offering and listing on the Hong Kong Stock Exchange
  • US$150 million senior notes offering
• Hydoo International Holding Limited in its US$212 million initial public offering and listing on the Hong Kong Stock Exchange (representing the underwriters)
• Cosmo Lady (China) Holdings Company Limited in its US$189 million initial public offering and listing on the Hong Kong Stock Exchange
• Fuguiniao Co., Ltd. in its US$150 million initial public offering and listing on the Hong Kong Stock Exchange (representing the underwriters)
• Dongpeng Holdings Company Limited in its US$94 million initial public offering and listing on the Hong Kong Stock Exchange (representing the underwriters)
• Yuzhou Properties in its US$200 million initial public offering and listing on the Hong Kong Stock Exchange
• Sunac China Holdings Limited in its US$400 million and US$350 million senior notes offerings
• Chiho-Tiande Group Limited in its US$200 million senior notes offering
• China Southern Airlines, Bona Film, Phoenix New Media and Focus Media in general corporate and listing compliance matters in the U.S.

Mergers and Acquisitions

• a buyer consortium led by Yunfeng Capital, TF Capital, GIC and their management in connection with the acquisition of Cellular Biomedicine Group in a going-private transaction valued at US$380 million
• Yunfeng Capital in its investment in Platinum Life Excellence Biotech (Beijing) Co., Ltd., Hangzhou Tigermed Consulting Co., Ltd. and WuXi Diagnostic Investment (Cayman) Limited
• two investors in their investments in Kuaishou Technology
• Hillhouse Capital in connection with its collaboration with Mayo Clinic involving services pertaining to hospital and medical management, education and other support for health care institutions in China
• founders of Adicon Holdings Limited in the sale of a majority interest to a consortium comprised of Meinian Onehealth Healthcare, funds managed by the Carlyle Group and Carlyle co-investors
• GIC in connection with its investment in Genpact Ltd.
• Zhaopin in its US$1 billion going-private acquisition by its founders
• Focus Media Holding Limited in its US$3.5 billion going-private transaction
• SEEK Limited in its investments in Coursera, Inc.; Hibob; Educalcp II, S.A. de C.V.; and GetLinks
• Weichai Power in its:
  • US$183 million investment in and joint venture with Ballard Power Systems
  • acquisitions of controlling stakes in Westport Fuel Systems and Power Solutions
• Bona Film in a strategic investment from Fosun